Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...
Trump's administration has cleared the way for arrests in schools of people suspected of being without legal status. And, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback